Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Infectious Diseases and Therapy|July 12, 2017
Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN StudiesSamuel E Wilson, Donald R Graham, Whedy Wang, et al.
Infectious Diseases and Therapy|October 9, 2016
Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical IsolatesJennifer I Smart, Gordon Ralph Corey, Martin E Stryjewski, et al.
Antimicrobial Agents and Chemotherapy|August 7, 2015
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA GuidanceRichard Pushkin, Steven L Barriere, Whedy Wang, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|December 22, 2012
The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazineEwa Karwatowska-Prokopczuk, Whedy Wang, Mei L Cheng, et al.
Diagnostic Microbiology and Infectious Disease|January 1, 2017
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolatesJennifer I Smart, G Ralph Corey, Martin E Stryjewski, et al.
American Heart Journal|April 1, 2009
Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitusFadi G Hage, Jaekyeong Heo, Billy Franks, et al.
BMC Cardiovascular Disorders|May 7, 2025
Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populationsLuke Zhang, Prachi Kulkarni, Farshad Farshidfar, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|October 17, 2021
Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trialHoracio Kaufmann, Ross Vickery, Whedy Wang, et al.
Statistics in Medicine|May 10, 2024
Novel non-linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methodsGuoqiao Wang, Whedy Wang, Brian Mangal, et al.
Circulation|July 21, 2010
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trialBenjamin M Scirica, Eugene Braunwald, Luiz Belardinelli, et al.
Pageof 2